Alnylam Pharma and Medison Pharma partner to commercialize RNAi therapeutics in Israel
Alnylam Pharmaceuticals and Medison Pharma announced an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. January 21, 2019